Tax-cover sale by Abeona (ABEO) director Silverstein disclosed in Form 4

Rhea-AI Filing Summary

Abeona Therapeutics director Christine Berni Silverstein reported a tax-related stock sale. On February 2, 2026, she sold 20,070 shares of common stock at a weighted average price of $5.0906 per share. After this transaction, she beneficially owned 137,722 shares, held directly.

The filing notes the sale was made to cover tax obligations arising from the vesting of restricted stock awards, indicating the transaction was tied to equity compensation rather than a discretionary open-market liquidation. The price range for the sales was between $5.09 and $5.12 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silverstein Christine Berni

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		20,070	D	$5.0906(2)	137,722	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Christine Silverstein	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abeona Therapeutics (ABEO) report for Christine Berni Silverstein?

Abeona director Christine Berni Silverstein reported selling 20,070 common shares. The sale occurred on February 2, 2026, at a weighted average price of $5.0906 per share, and was disclosed on a Form 4 insider trading report filed under Section 16 rules.

Why did the Abeona (ABEO) director sell 20,070 shares according to the Form 4?

The shares were sold to cover tax obligations from restricted stock vesting. The filing explains the transaction was related to tax liabilities triggered when restricted stock awards vested, indicating it was compensation-linked rather than a purely discretionary stock sale decision.

What price did Christine Berni Silverstein receive for her Abeona (ABEO) share sale?

The weighted average sale price was $5.0906 per share. The Form 4 notes the 20,070 shares were sold in multiple trades at prices ranging from $5.09 to $5.12 inclusive, and the reporting person can provide full trade details upon request.

How many Abeona (ABEO) shares does the director own after the reported sale?

After the transaction, she beneficially owned 137,722 common shares. The Form 4 states this post-transaction holding is owned directly, reflecting her remaining equity stake following the 20,070-share sale completed on February 2, 2026.

What role does Christine Berni Silverstein hold at Abeona Therapeutics (ABEO)?

She is reported as a director of Abeona Therapeutics Inc. The Form 4 identifies her relationship to the issuer by checking the “Director” box, with no officer title or 10% owner status indicated, clarifying her governance role at the company.

What trading range is disclosed for the Abeona (ABEO) insider share sale?

The sale transactions occurred between $5.09 and $5.12 per share. The Form 4 explains that the reported $5.0906 price is a weighted average and that detailed trade-by-trade price information is available to the issuer, shareholders, or SEC staff upon request.